stockrow
Saturday 7 November 2026
Export NVCT’s income statement to Excel — free account
Nuvectis Pharma, Inc.
NVCT Healthcare Biotechnology
- EPS
- −131.9%
- Free cash flow
- −34.6%
Quarter to September 2026, against a year earlier
20.81
3.05
+17.17%
Follow NVCT
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (66.98%) | (233.30%) | (168.24%) | (205.30%) |
+8 more TTM periods Free account |
|
| (57.20%) | (122.61%) | (106.54%) | (114.76%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(39.84%) | (333.35%) | (208.08%) | (156.80%) | |
Free Cash Flow per Share |
(1.37) | (0.83) | (0.78) | (0.73) | |
Free Cash Flow |
(40.29) | (19.51) | (18.35) | (16.01) | |
| Other line items | |||||
Cash ROIC |
(15.07%) | (62.45%) | (46.62%) | (31.99%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.80 | 0.64 | 0.62 | 0.55 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.37) | (0.83) | (0.78) | (0.73) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026